GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells
European Journal of Endocrinology · 10.01.2023 · 188 (1) · 144-157
DOI: 10.1093/ejendo/lvac004 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Endocrinology, online erschienen am 16.01.2023. Verfasst von Morten S Hansen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Endocrinology Laboratory (KMEB), Department of Endocrinology, Odense University Hospital, Odense C DK-5000, Denmark. Hauptthemen laut MEDLINE: Osteoclasts, Bone Resorption. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Region of Southern Denmark, Versus Arthritis, Odense University Hospital.
Abstract (Originalsprache)
Objective
Drugs targeting the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) are emerging as treatments for type-2 diabetes and obesity. GIP acutely decreases serum markers of bone resorption and transiently increases bone formation markers in short-term clinical investigations. However, it is unknown whether GIP acts directly on bone cells to mediate these effects. Using a GIPR-specific antagonist, we aimed to assess whether GIP acts directly on primary human osteoclasts and osteoblasts.
Methods
Osteoclasts were differentiated from human CD14+ monocytes and osteoblasts from human bone. GIPR expression was determined using RNA-seq in primary human osteoclasts and in situ hybridization in human femoral bone. Osteoclastic resorptive activity was assessed using microscopy. GIPR signaling pathways in osteoclasts and osteoblasts were assessed using LANCE cAMP and AlphaLISA phosphorylation assays, intracellular calcium imaging and confocal microscopy. The bioenergetic profile of osteoclasts was evaluated using Seahorse XF-96.
Results
GIPR is robustly expressed in mature human osteoclasts. GIP inhibits osteoclastogenesis, delays bone resorption, and increases osteoclast apoptosis by acting upon multiple signaling pathways (Src, cAMP, Akt, p38, Akt, NFκB) to impair nuclear translocation of nuclear factor of activated T cells-1 (NFATc1) and nuclear factor-κB (NFκB). Osteoblasts also expressed GIPR, and GIP improved osteoblast survival. Decreased bone resorption and improved osteoblast survival were also observed after GIP treatment of osteoclast–osteoblast co-cultures. Antagonizing GIPR with GIP(3–30)NH2 abolished the effects of GIP on osteoclasts and osteoblasts.
Conclusions
GIP inhibits bone resorption and improves survival of human osteoblasts, indicating that drugs targeting GIPR may impair bone resorption, whilst preserving bone formation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Endocrinology Laboratory (KMEB), Department of Endocrinology, Odense University Hospital, Odense C DK-5000, Denmark.
- Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense C DK-5000, Denmark.
- Institute of Metabolism and Systems Research (IMSR) and Centre for Diabetes, Endocrinology and Metabolism (CEDAM), University of Birmingham, Birmingham B15 2TT, United Kingdom.
- Centre for Membrane Proteins and Receptors (COMPARE), Universities of Birmingham and Nottingham, Birmingham B15 2TT, United Kingdom.
- Clinical Cell Biology, Department of Pathology, Odense University Hospital, Odense C DK-5000, Denmark.
- Department of Molecular Medicine, University of Southern Denmark, Odense C DK-5000, Denmark.
ORCID-Profile: Rachael A Wyatt, Bolette Hartmann, Caroline M Gorvin, Morten Frost
Förderung
- Region of Southern Denmark
- Versus Arthritis
- Odense University Hospital
- British Heart Foundation
- Government Department of Business, Energy and Industrial Strategy
- Wellcome Trust
- Novo Nordisk Foundation
- Medical Research Council
Zitieren
APA
Hansen, M. S., Søe, K., Christensen, L. L., Fernandez-Guerra, P., Hansen, N. W., Wyatt, R. A., Martin, C., Hardy, R. S., Andersen, T. L., Olesen, J. B., Hartmann, B., Rosenkilde, M. M., Kassem, M., Rauch, A., Gorvin, C. M., & Frost, M. (2023). GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells. European Journal of Endocrinology, 188(1), 144-157. https://doi.org/10.1093/ejendo/lvac004
Vancouver
Hansen MS, Søe K, Christensen LL, Fernandez-Guerra P, Hansen NW, Wyatt RA, et al. GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells. European Journal of Endocrinology. 2023;188(1):144-157. doi:10.1093/ejendo/lvac004
BibTeX
@article{Hansen2023,
author = {Hansen, Morten S and Søe, Kent and Christensen, Line L and Fernandez-Guerra, Paula and Hansen, Nina W and Wyatt, Rachael A and Martin, Claire and Hardy, Rowan S and Andersen, Thomas L and Olesen, Jacob B and Hartmann, Bolette and Rosenkilde, Mette M and Kassem, Moustapha and Rauch, Alexander and Gorvin, Caroline M and Frost, Morten},
title = {GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells},
journal = {European Journal of Endocrinology},
year = {2023},
volume = {188},
number = {1},
pages = {144--157},
doi = {10.1093/ejendo/lvac004}
}
EUVIMED